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prostate cancer. The aim of this study is to determine the signiﬁcance of Ki-67 and ERG as a biomarker of patient outcome for
prostate cancer patients treated with radiotherapy.
Methods and materials. Pretreatment archival prostate biopsy tumor tissue was available from 339 stage T1–T4 prostate cancer
patients treatedwith external beam radiotherapy alone or in combinationwith androgendeprivation therapy (ADT) between 2003
and 2005. All patientswere diagnosed by needle biopsy andnone of themhad evidence ofmetastasis. Parafﬁn-embedded prostate
cancer tissue was available in 88/339 patients. Immunohistochemical staining of Ki-67 was used to determine the proliferation
index in each case. The Ki-67 was expressed as a percentage (<3 vs ≥3) of immunoreactive tumor cells to the total counted tumor
cells. ERG-EP11 monoclonal antibody was used to determine the presence of ERG protein. A positive reaction was considered
if the tumor cells showed a nuclear staining to ERG-EP11 antibody. Factors associated to failure, survival and progression were
analysed. Estimates of survival were determined using Kaplan–Meier methods. Unadjusted and adjusted hazard ratios were
calculated using the Cox regression model.
Results. Mean age was 70 years (range 56–84). T1–T2 stage 276 patients (81.5%), T3 61 patients (18%). Initial PSA (ng/ml) was <20,
279 patients (82.4%) and >20, 60 patients (17.6%). Forty-nine percent of patients had Gleason score≥7. Median radiation dose
to prostate was 74Gy. Whole pelvic irradiation was administered in 44%, and 75% received ADT. Expression of Ki-67≥3% was
observed in 64/82 patients (78%) and for ERG+ in 54/82 patients (66%) for the analyzed cohort. Intermediate (Ki-67≥3%, 13/20
pts, 65%, and ERG+, 14/20 pts, 70%), and high-risk (Ki-67≥3%, 45/53 pts, 85%, and ERG+, 35/53 pts, 66%) groups were the highest
expression observed (p<0.05). With a median follow-up of 7.28 years (range 1.4–15 years), the 10-year OS for Ki-67<3 vs Ki-67≥3%
was 89% and 87%, and 93% and 85% for ERG− vs ERG+. The 10-year BRFS for Ki-67<3 vs Ki-67≥3% was 100% and 73% (p 0.06), and
87% and 77% for ERG− vs ERG+. On univariate analysis (for entire cohort, 339 pts), initial psa (p 0.01), Gleason (p 0.001), and nadir
psa post-RT (p 0.001) were signiﬁcantly associated with biochemical failure. Ki-67≥3% was associated with a trend biochemical
failure (p 0.063). Estimates of survival and Cox regression model for 88/339 pts will be presented.
Conclusions. Expression of Ki-67≥3% and ERG+ obtained from pretreatment prostate cancer biopsies could be used as predictor
biomarkers of advanced stages, failure and survival after treatment with radiotherapy.
http://dx.doi.org/10.1016/j.rpor.2013.03.811
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Introduction. The intensity-modulated radiotherapy (IMRT) for prostate cancer permits further dose escalation and appears to be
less toxic compared to three-dimensional conformal radiotherapy (3D-CRT).
Objectives. To report the incidence of treatment-related toxicity after IMRT for prostate cancer.
Methods. Between January 2009 and December 2011, 79 patients with prostate cancer were treated with IMRT with doses ranging
from76 to 80Gy in 64patientswith stagesT1–T4prostate cancer and66–76Gy in 15patientswith a recurrence after prostatectomy.
The median follow-up was 20.95 months (6.1–39.6). Gastrointestinal (GI) and genitourinary (GU) posttreatment toxicities were
graded according to the RTOG Acute and Late Radiation Morbidity Scoring Criteria/Schema. Sexual toxicity was graded according
to theNational Cancer Institute’s CommonTerminology Criteria for Adverse Events (CTC 4.0).We evaluated the toxicity presented
during radiotherapy=0 months (0m), at 3 months (3m) and 6 months (6m) after completion of therapy (Acute Toxicity). Finally,
we evaluated the toxicity from 6 months of completing treatment to the last follow-up date (Late Toxicity).
Results. Grade≥2 toxicities of non-operated patients: Acute GU toxicity: 0m: 33.3%; 3m: 3.2%; 6m: 1.6%. Acute GI toxicity: 0m:
1.6%; 3m: 0%; 6m: 0%. Late GU toxicity: 1.6%. Late GI toxicity: 0%. Late sexual toxicity: 31%. Grade≥2 toxicities of operated
patients: Acute GU toxicity: 0m: 13.3%; 3m: 0%; 6m: 0%. Acute GI toxicity: 0m: 0%; 3m: 0%; 6m: 0%. Late GU toxicity: 7.1%. Late
GI toxicity: 0%. Late sexual toxicity was: 100%.
Conclusions. IMRT was feasible and sure, with low rates of serious acute toxicity and without any late grade 3–4 genitourinary or
gastrointestinal toxicity despite the delivery of high radiation dose levels. Many non-operated patients preserved erection long
term. More patients and longer follow-up are needed to conﬁrm our results.
http://dx.doi.org/10.1016/j.rpor.2013.03.812
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Introduction. Acute grade 3 toxicity is uncommon during stereotactic body radiation therapy (SBRT) for low-risk prostate cancer
(PCa) using robotic radiosurgery (Katz, 2010; Freeman, 2011).
Purpose. Single-institution single-arm prospective study in low-intermediate PCa. Endpoint: To assess acute toxicity (to
exclude>5% men have grade3 GU or any grade3 GI).
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Methods. Since 5-2012 ﬁfteenNCCN PCa patientswere treatedwith helical tomotherapy. Approved by clinical research ethics com-
mittee. Exclusion criteria: Gleason score≥8, PSA>20, cT3b-4, cN1, cM1, IPSS≥20, history of acuteurinary retention. CT-simulation
using CombiﬁxTM with empty rectum and 200ml bladder ﬁlled through urine catheter. CTV included prostate± seminal vesicles.
PTV margins were 3–10mm. Total dose to 95% PTV was 43.84–45.20Gy in 8 fx of 5.48–5.65Gy on alternate days, according to the
risk group (low vs. intermediate-high). EQD2=74.4–78.2Gy (a/b3) or 87.4–92.3Gy (a/b1.5). Rectal constraints: V43<10%, V40<15%,
V37<20%, V34<30%, V28<40%. MVCT for on-line correction in every fraction. Cleansing enema prior each fraction. Bladder
volume during irradiation was controlled through: (1) bladder ﬁlling using urine catheter (1st patient), or (2) measuring urine
volume right after every fraction to provide feedback about the delay between water intake and treatment. All men received
neoadjuvant-concomitant ADT.
Results. Patient characteristics: cT1 (53%), T2b (30%), T3a (17%), GS6 (46%), GS7 (54%), median PSA=8.2ng, median IPSS=5. CTCAE
acute GI toxicity: 0% grade 2, 54% grade 1 (abdominal pain, frequency, diarrhoea), 46% grade 0. GU ﬁgures: 7% grade 2 (dysuria),
66% grade 1 (dysuria, frequency, urgency, nocturia), 27% grade 0. In total, after 120 MVCT, the standard deviation of the mean
individual patient corrections in anterior–posterior direction was 1.5mm. Irradiation time was 520±30 s. A 25min time slot is
dedicated to every fraction.
Conclusion. To our knowledge, this is the ﬁrst clinical report about extreme hypofractionation in PCa using helical tomotherapy.
In this series high-dose radiotherapy delivered in eight fractions had an acceptable acute toxicity proﬁle.
http://dx.doi.org/10.1016/j.rpor.2013.03.813
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Introduction. Intermittent androgen deprivation for prostate-speciﬁc antigen (PSA) elevation after radiotherapy (RT) may improve
quality of life and delay hormone resistance.
Purpose. We compared biochemical control and quality of life with intermittent (6 months) versus continuous (36 months) andro-
gen deprivation in a noninferiority randomized trial in patients with biochemical progression (BR) after RT following Phoenix
PSA criteria.
Materials and methods. Seventy-seven patients were included in this multicentre phase III trial between 2005 and 2009. Median
follow-up was 2 years. Patients were stratiﬁed according Gleason score (GS), which was classiﬁed as low risk if GS<6 and 7 (3 + 4)
and high risk with GS of 7 (4 + 3) and >7. Patients were followed with PSA determinations and quality of life assessments (QLQ
C-30 and QLQ PR-25) every 6 months for a period of 3 years. BR was deﬁned as a PSA determination of 4 or >4ng/ml.
Results. Thirty-eight and 39 patients were included in intermittent and continuous group respectively. Mean age was 74.3 (±6.5).
Previous moderate comorbidity was present in 51 patients. TNM stage at the diagnostic was T1c (20.5%), T2a (20.5%), T2b-c
(24.7%) and T3a-b (33%). GS was low risk (as previously deﬁned) in 43 patients (58.1%) and high risk in 31 patients (41.9). GS was
well balanced between groups. BR was seen in 8 patients (distant metastases in one patient) in the intermittent group vs. 2 in
the continuous group. QLQ-C30 score did not show any statically difference between groups of hormonal treatment. QLQ PR-25
assessment showed statistically signiﬁcant changes in urinary symptoms between baseline and visit 9 between intermittent and
continuous deprivation (p-value=0.036) and the absolute value of the symptoms associated with hormone therapy at baseline
(p-value=0.037). Conclusions. In this preliminary analysis no statistical differences in BR were seen between intermittent (6
months) and continuous (36 months) hormonal deprivation.
http://dx.doi.org/10.1016/j.rpor.2013.03.814
